The immunosuppressive agent mycophenolate mofetil markedly potentiates the activity of lobucavir [1R(1α,2β,3α)]-9-[2,3-bis(hydroxymethyl)- cyclobutyl]guanine against different herpes viruses

Transplantation

Volumn 67, Issue 5, 1999, Pages 760-764

  Neyts, Johan ^a   De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; LOBUCAVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CYTOMEGALOVIRUS; DRUG POTENTIATION; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PRIORITY JOURNAL; VERO CELL; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0033558985     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199903150-00022     Document Type: Article

References (20)

1. Ransom JT. Mechanism of action of mycophenolate mofetil. Ther Drug Monitor 1995; 17: 681.
2. Fulton B, Markham A. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 1996; 51: 278.
3. Suthanthiran M, Morris RE, Strom TB. Immunosuppressants: cellular and molecular mechanism of action. Am J Kidney Dis 1996; 28: 159.
4. Kobashigawa JA. Mycophenolate mofetil in cardiac transplantation. Curr Opin Cardiol 1998; 13: 117.
5. Sievers TM, Rossi SJ, Ghobrial RM, et al. Mycophenolate mofetil. Pharmacotherapy 1997; 17: 1178.
6. Field AK, Tuomari AV, McGeever-Rubin B, et al. (±)-(1α,2β,3α)-9-[2,3-bis(hydroxymethyl)cyclobutyl] guanine [(±)-BHCG or SQ 33054]: a potent and selective inhibitor of herpesviruses. Antiviral Res 1990; 13: 41.
7. Braitman A, Swerdel MR, Olsen SJ, et al. Evaluation of SQ 34,514: pharmacokinetics and efficacy in experimental herpesvirus infections in mice. Antimicrob Agents Chemother 1991; 35: 1464.
8. Yamanaka G, Tuomari AV, Hagen M, et al. Selective activity and cellular pharmacology of (1R-1α,2β,3α)-9-[2,3-bis(hydroxymethyl)cyclobutyl]guanine in herpesvirus-infected cells. Mol Pharmacol 1991; 40: 446.
9. Koyano S, Suzutani T, Yoshida I, Azuma M. Analysis of phosphorylation pathways of antiherpesvirus nucleosides by varicella-zoster virus-specific enzymes. Antimicrob Agents Chemother 1996; 40: 920.
10. Dunkle LM. Lobucavir: new broad spectrum antiviral agent. In: Sapienza DM, ed. Antivirals, latest preclinical and clinical developments for infectious diseases, pp. 1-4. International Business Communications, Inc., Southborough, MA, 1998.
11. Terry BJ, Cianci CW, Hagen ME. Inhibition of herpes simplex virus type 1 DNA polymerase by of [1R(1α,2β,3α)]-9-[2,3-bis(hydroxymethyl)cyclobutyl]guanine. Mol Pharmacol 1991; 40: 591.
12. Izuta S, Shimada N, Kitagawa M, Suzuki M, Kojima K, Yoshida S. Inhibitory effects of triphosphate derivatives of oxetanocin G and related compounds on eukaryotic and viral DNA polymerases and human immunodeficiency virus reverse transcriptases. J Biochem 1992; 112: 81.
13. Tenney DJ, Yamanaka G, Voss SM, et al. Lobucavir is phosphorylated in human cytomegalovirus-infected and uninfected cells and inhibits the viral DNA polymerase. Antimicrob Agents Chemother 1997; 41: 2680.
14. Neyts J, Andrei G, De Clercq E. The novel immunosuppressive agent Mycophenolate Mofetil markedly potentiates the antiherpes virus activities of acyclovir, ganciclovir and penciclovir in vitro and in vivo. Antimicrob Agents Chemother 1998; 42: 216.
15. De Clercq E. Trends in the development of new antiviral agents for the chemotherapy of infections caused by herpesviruses and retroviruses. Rev Med Virol 1995; 5: 149.
16. De Clercq E, Descamps J, Verhelst G, et al. Comparative efficacy of different antiherpes drugs against different strains of herpes simplex virus. J Infect Dis 1980; 141: 563.
17. Baba M, Pauwels R, Balzarini J, Herdewijn P, De Clercq E, Desmyter J. Ribavirin antagonizes inhibitory effects of pyrimidine 2′,3′-dideoxynucleosides but enhances inhibitory effects of purine 2′,3′-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob Agents Chemother 1987; 31: 1613.
18. Patterson JL, Fernandez-Larsson R. Molecular mechanism of ribavirin. Rev Infect Dis 1990; 12: 1139.
19. Balzarini J, De Clercq E. Assay method for monitoring the inhibitory effects of antimetabolites on the activity of inosinate dehydrogenase in intact human CEM lymphocyte cells. Biochem J 1992; 287: 785.
20. Bullingham R, Monroe S, Nicholls A, Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996; 36: 315.